Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finance Watch: US, Hong Kong IPOs Are Hot, But Sirnaomics Stays Private

The US- And China-Based Firm Raised A $105m Series E Round

Executive Summary

Private Company Edition: Sirnaomics planned to go public after its series D, but its new venture capital does not prevent it from doing so in the near term. Also, Vida Ventures and Novalis Biotech raised new VC funds to back start-ups and ArriVent launched with up to $150m in series A cash.

You may also be interested in...



US-Listed China Biotech Shares Hit By Broad China Cybersecurity Review

First DIDI, then other recently US-listed tech companies and now biotech companies are seeing share drops as China widens its cybersecurity reviews. But investors are also seeing other corrections from recent highs.

HutchMed CEO On Novel Drug Pricing Strategy In China

A successful IPO on the Hong Kong Stock Exchange will jump-start the company’s R&D and new drug approvals, says HutchMed's CEO in an interview.

China's CARsgen Raises $400m In Third-Largest Biotech IPO This Year

Chinese CAR-T therapy developer raises new funds to progress pipeline in over-subscribed IPO which ranks as the third-largest globally in the biotech sector to date this year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel